Navigation Links
Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
Date:6/12/2013

of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement.  Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products.  In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products.  We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products.  In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.  We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products.  Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates.  Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Amgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma
2. Amgen To Webcast Investor Meeting At Upcoming American Society Of Clinical Oncology Annual Meeting
3. Amgen And Astellas Announce Japan Alliance
4. Amgen to Present at the Deutsche Bank 38th Annual Healthcare Conference
5. Amgen To Present At The UBS Global Life Sciences Conference
6. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
7. Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
8. Amgen, Hospira and Sandoz Named Among Top Pharmaceutical Companies with Greatest Biosimilar Drug Potential in United States
9. Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
10. Amgens First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96
11. Amgen Announces Webcast of 2013 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 The Parenteral Drug ... harmonize global post-approval changes protocols. The ... the topic expressed by industry participants and regulatory authority ... this month in Washington, DC . ... on hand for the workshop. Attendees indicated openness to ...
(Date:9/19/2014)... 19, 2014 /PRNewswire-iReach/ -- "United States ... provides key market data on the ... The report provides value, in millions ... units) within market categories – Bronchoscopes, ... & Gastroscopes, Duodenoscopes, Laparoscopes, Hysteroscopes, Sinuscopes, ...
(Date:9/19/2014)... , Sept. 19, 2014  The board of ... declared a quarterly cash dividend of $0.42 per share.  ... 17, 2014 to stockholders of record at the close ... AbbVie AbbVie is a global, research-based biopharmaceutical company formed ... is to use its expertise, dedicated people and unique ...
Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5
... 31, 2011 Reportlinker.com announces that a ... its catalogue: Germany Surgical ... http://www.reportlinker.com/p0254518/Germany-Surgical-Equipment-Market-Outlook-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment Germany ... Summary GlobalData,s ...
... Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX ), an ... the third quarter ended September 30, 2011 and provided ... (FDA) approval of EXPAREL™ (bupivacaine liposome injectable suspension) and ... "With the broad postsurgical pain management label granted ...
Cached Medicine Technology:Germany Surgical Equipment Market Outlook to 2016 2Germany Surgical Equipment Market Outlook to 2016 3Germany Surgical Equipment Market Outlook to 2016 4Germany Surgical Equipment Market Outlook to 2016 5Germany Surgical Equipment Market Outlook to 2016 6Germany Surgical Equipment Market Outlook to 2016 7Germany Surgical Equipment Market Outlook to 2016 8Germany Surgical Equipment Market Outlook to 2016 9Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 2Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 3Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 4Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 5Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 6Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 7Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 8Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 9
(Date:9/20/2014)... Recently, Best Cheap Hosting USA (best-cheap-hosting-usa.com), a leading ... The new site provides the latest reviews on ... Here, people can find a lot of information ... has recommended some excellent web hosting suppliers for ... web hosting suppliers, InMotion ( http://www.best-cheap-hosting-usa.com/go/InMotion/ ), keeps ...
(Date:9/20/2014)... September 20, 2014 Plumbing construction ... out of 5, indicating a moderately favorable purchasing environment ... score reflects current and future pricing trends that will ... prices. Other factors that negatively affect buyer power are ... construction and the moderate switching costs. Buyers benefit, however, ...
(Date:9/20/2014)... 20, 2014 The Arizona Advanced ... is celebrating National Manufacturing Day by opening its doors ... processing and additive manufacturing labs will be offered between ... at MCC’s Southern and Dobson campus (1833 W. Southern ... Lot D. , The AzAMI at MCC was established ...
(Date:9/19/2014)... Nearly 780 Risperdal lawsuits are moving ... a meeting took place to discuss the next steps ... the court’s mass tort program. Attorneys for the plaintiffs ... at the Complex Litigation Center in Philadelphia’s City Hall ... The Risperdal lawsuits filed against Johnson & Johnson and ...
(Date:9/19/2014)... September 19, 2014 BearCom, a ... today detailed the key role played by instant, ... in the healthcare industry. , “In healthcare, ... care – and in emergency situations, can save ... life and death,” said Hugh Johnston, Product & ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 2Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 3Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 4
... CT angiography utilizing prospective electrocardiographic (ECG) gating produces ... dose when compared to retrospective ECG gating, according ... Roentgen Ray Society,s annual meeting. , The study ... the University Hospitals Case Medical Center, in Cleveland, ...
... TUESDAY, May 3 (HealthDay News) -- The U.S. Food ... are cracking down on manufacturers of over-the-counter products that ... The agencies jointly sent letters to companies including ... that their products are unproven and violate federal law, ...
... HealthDay Reporter , TUESDAY, May 3 (HealthDay News) -- ... lower their blood sugar level more effectively than just receiving ... review of data. After analyzing the results of ... for longer periods of time was better at bringing blood ...
... to play a key role in tumor survival, a research ... MD Anderson Cancer Center reports in an advance online publication ... suggests that the little-studied protein binds to the tumor-suppressing protein ... it for destruction by proteasomes, which degrade proteins and recycle ...
... HealthDay Reporter , TUESDAY, May 3 (HealthDay News) ... new U.S. study have TVs available for children to watch, ... Academy of Pediatrics, guidelines for television exposure in young kids. ... at daycares may be missing out on the kind of ...
... Cell biologist Daniel Gottschling, Ph.D., a member of the ... been elected to membership in the National Academy of Sciences. ... that can be accorded a U.S. scientist or engineer. "I ... peers," said Gottschling, who will be inducted into the Academy ...
Cached Medicine News:Health News:Low-dose chest CT effective in reducing radiation for evaluation of cardiothoracic surgery patients 2Health News:U.S. Officials Take Aim at Questionable STD Products 2Health News:Structured Exercise Programs Help Lower Blood Sugar, Study Finds 2Health News:Structured Exercise Programs Help Lower Blood Sugar, Study Finds 3Health News:Protein identified as enemy of vital tumor suppressor PTEN 2Health News:TVs Common in Daycare Centers, Flouting Guidelines 2Health News:TVs Common in Daycare Centers, Flouting Guidelines 3Health News:Cell biologist Daniel Gottschling elected to National Academy of Sciences 2
... immersion objective has a higher numerical aperture ... media helps eliminate surface,reflections and provides an ... excellent objective for fluorescence, brightfield and DIC ... correction collar that allows it to be ...
... is a very versatile light source ... variety of applications anytime a Zeiss ... illumination with optimum protection without heating ... most economical cold-light source that completes ...
... a complete line of ... halogen light sources that ... A solid-state dimmer provides ... our exclusive Modulamp assembly ...
Standard 20x long working distance objectives for greater magnifications of your microtools....
Medicine Products: